Verrica Pharmaceuticals Inc. (VRCA)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Verrica Pharmaceuticals Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | 3.31 | 3.50 | 3.31 | 3.46 | 30,577 |
| Nov 3, 2026 | 3.35 | 3.42 | 3.25 | 3.29 | 44,951 |
| Nov 2, 2026 | 3.40 | 3.62 | 3.20 | 3.21 | 55,798 |
| Oct 30, 2026 | 3.42 | 3.49 | 3.25 | 3.35 | 33,787 |
| Oct 29, 2026 | 3.48 | 3.62 | 3.39 | 3.42 | 29,721 |
| Oct 28, 2026 | 3.45 | 3.56 | 3.39 | 3.48 | 22,370 |
| Oct 27, 2026 | 3.36 | 3.52 | 3.33 | 3.47 | 27,987 |
| Oct 26, 2026 | 3.55 | 3.68 | 3.39 | 3.42 | 21,942 |
| Oct 23, 2026 | 3.76 | 3.76 | 3.40 | 3.53 | 21,006 |
| Oct 22, 2026 | 3.50 | 4.17 | 3.50 | 3.83 | 109,909 |
| Oct 21, 2026 | 3.46 | 3.64 | 3.44 | 3.63 | 60,441 |
| Oct 20, 2026 | 3.44 | 3.56 | 3.30 | 3.47 | 77,185 |
| Oct 19, 2026 | 3.61 | 3.65 | 3.42 | 3.44 | 79,831 |
| Oct 16, 2026 | 3.85 | 3.95 | 3.48 | 3.60 | 116,474 |
| Oct 15, 2026 | 3.92 | 3.95 | 3.75 | 3.78 | 64,299 |
| Oct 14, 2026 | 3.54 | 3.92 | 3.50 | 3.83 | 54,857 |
| Oct 13, 2026 | 3.99 | 4.38 | 3.51 | 3.58 | 85,859 |
| Oct 12, 2026 | 4.20 | 4.20 | 4.00 | 4.01 | 48,708 |
| Oct 9, 2026 | 4.37 | 4.37 | 4.06 | 4.11 | 46,551 |
| Oct 8, 2026 | 4.14 | 4.29 | 4.05 | 4.18 | 37,188 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Kirby John J. | Interim CFO | Purchase | 5.0K | $24.6K | Aug 18, 2026 |
 Rosenberg Noah L. | CMO | Purchase | 2.0K | $10.0K | Aug 18, 2026 |
 Zawitz David | Chief Operating Officer | Purchase | 6.0K | $29.9K | Aug 17, 2026 |
| Rosenberg Noah L. | CMO | Purchase | 4.2K | $20.6K | Aug 17, 2026 |
 Rieger Jayson | CEO and President | Purchase | 5.0K | $24.6K | Aug 17, 2026 |
| Rieger Jayson | CEO and President | Purchase | 20.0K | $101.2K | Aug 14, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Paul B Manning · may incl. warrants· filed Nov 2025 | 8.1M | 46.9% | 13D |
Caligan Partners LP · also on 13F· may incl. warrants· filed Dec 2025 | 6.5M | 10.0% as filed | 13D |
 BKB Growth Investments, LLC 10% Owner | 3.3M | 19.5% | FORM 4 |
Caligan Partners LP | 923.9K | 5.4% | 13F |
Affinity Asset Advisors, LLC · also on 13F· filed Jan 2026 | 707.3K+176.8K via warrants | 5.1% | 13G |
CANNELL CAPITAL LLC | 783.9K | 4.6% | 13F |
Affinity Asset Advisors, LLC | 707.3K | 4.1% | 13F |
Velan Capital Investment Management LP | 471.6K | 2.7% | 13F |
Armistice Capital, LLC · also on 13F· may incl. warrants· filed Feb 2026 | 439.7K | 2.6% | 13G |
ARMISTICE CAPITAL, LLC | 426.3K | 2.5% | 13F |
Insiders
- Kirby John J.Interim CFO
- Rosenberg Noah L.CMO
- Zawitz DavidChief Operating Officer
- Rieger JaysonCEO and President
- Eichenfield LawrenceDirector
- Nguyen DiemDirector
- PRYGOCKI MARK A SRDirector
- Corcoran GavinDirector
- Manning Paul BDirector
- Hayes Christopher G.CHIEF LEGAL OFFICER
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications.
The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
based on 17.18M shares outstanding
US30d Avg
52.65K
60d Avg
51.99K
90d Avg
70.78K